RecruitingPhase 2NCT04063540

Acid-Sensing Ion Channel and Migraine Disease Proof of Concept Study on the Efficacy of Amiloride in the Prophylaxis of Migraine Aura


Sponsor

Centre Hospitalier Universitaire de Nice

Enrollment

40 participants

Start Date

Aug 11, 2020

Study Type

INTERVENTIONAL

Conditions

Summary

Recent data suggest involvement of Acid-Sensing Ion Channel channels in the pathophysiology of migraine making these channels a therapeutic target of migraine disease. The implication of Acid-Sensing Ion Channels is discussed through Acid-Sensing Ion Channel-1 which is the most expressed Acid-Sensing Ion Channel channel subtype in the central nervous system. In a mouse model, cortical spreading depression is inhibited by different Acid-Sensing Ion Channel blockers including amiloride which is a non-selective blocker of the Acid-Sensing Ion Channel-1 channel. From a translational perspective, an efficacy of amiloride on a series of migraine patients suffering from severe aura in open conditions. The APAM study is a proof-of-concept study that aims to evaluate the effect of amiloride in the prophylaxis of migraine with aura. This is a randomized crossover study versus placebo conducted in 3 French headache centers.


Eligibility

Min Age: 18 YearsMax Age: 80 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Amiloride and a drug called Placebos for people with migraine with aura. The study is currently recruiting participants at 5 locations. People eligible for this study include aged 18 Years to 80 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGAmiloride

Treatment by Amiloride vs placebo in crossover

DRUGPlacebos

Treatment by Amiloride vs placebo in crossover


Locations(5)

Hôpital Pierre Wertheimer

Bron, France

CHU Gabriel Montpied

Clermont-Ferrand, France

AP-HM

Marly, France

CHU de Montpellier

Montpellier, France

CHU de NICE

Nice, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04063540


Related Trials